Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus METHSCOPOLAMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus METHSCOPOLAMINE BROMIDE.
BENTYL vs METHSCOPOLAMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
Antimuscarinic agent that competitively antagonizes acetylcholine at muscarinic receptors, inhibiting gastrointestinal motility and secretions.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
2.5 to 5 mg orally three times daily and at bedtime; or 0.25 to 1 mg subcutaneously or intramuscularly every 6 to 8 hours.
None Documented
None Documented
Clinical Note
moderateMethscopolamine bromide + Topiramate
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Topiramate."
Clinical Note
moderateMethscopolamine bromide + Methadone
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Methadone."
Clinical Note
moderateMethscopolamine bromide + Mirabegron
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Mirabegron."
Clinical Note
moderate1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
Terminal elimination half-life is approximately 1.5-2 hours in adults; clinical context: requires frequent dosing (every 4-6 hours) to maintain therapeutic effect.
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% excreted in urine within 24 hours, with the remainder eliminated in feces via biliary excretion.
Category C
Category A/B
Anticholinergic
Anticholinergic
Methscopolamine bromide + Sufentanil
"The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Sufentanil."